The World Health Organization (WHO) Global TB Programme (GTB) would like to announce an upcoming Guideline Development Group meeting for the update of the WHO consolidated guidelines on the treatment of drug-resistant tuberculosis, to be held 24-27 June 2024 in Versoix, Switzerland.
The current World Health Organization (WHO) recommendations for treating persons with drug resistant TB are included in the WHO consolidated Guidelines for treatment of drug-resistant tuberculosis, released in 2022. In recent years, new combinations of anti-TB medicines in various durations of treatment have been tested in clinical trials by researchers and national TB programmes. As the use of new regimens of treatment offers the possibility of improved outcomes for patients, it is imperative that WHO reviews new evidence in a timely manner to determine if new recommendations on MDR/RR-TB treatment can be made.
The objectives of this GDG meeting are:
- To review evidence on the efficacy and safety of novel 6- and 9-month regimens for patients with MDR/RR-TB or pre-XDR-TB;
- To consolidate all treatment recommendations in Module 4: Treatment of the WHO Consolidated TB Guidelines.